Idiopathic Pulmonary Fibrosis (IPF) Pipeline to Witness Huge R&D Investment in the Coming Years

  • Published: September 2017

According to a new research report “Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Intelligence, the IPF exhibits strong pipeline with estimated 104 drug candidates in 2017.


IPF pipeline in 2017

The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF.

Insights on pipeline segments

As per the findings of research, it was found that most of the IPF drug candidates target chemokine receptor. The analysis was also done based on route of administration and it was found that major drug candidates are being developed to be administered by oral route.

More than 10 drug candidates received Orphan Drug Designation (ODD)

The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) granted ODD to more than 10 drugs. As per the FDA, its Office of Orphan Products Development (OOPD) mission is to advance the evaluation and development of products (drugs, biologics, devices, or medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions. The drug candidate of MediciNova, Inc. has been granted Orphan Drug Designation for the treatment of IPF, which will provide MediciNova with seven years of marketing exclusivity if it is approved for IPF. Some of the key players developing drugs candidates for the treatment of IPF include Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and others.

IPF Pipeline Analysis

  • By route of administration
  • By molecule type
  • By company
  • By phase